Final Results from Arq 197-209: A Global Randomized Placebo-controlled Phase 2 Clinical Trial of Erlotinib Plus ARQ 197 Versus Erlotinib Plus Placebo in Previously Treated EGER-inhibitor Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

被引：0

作者：

Von Pawel, J. ^{[1
]}

Akerley, W. ^{[2
]}

Brugger, W. ^{[3
]}

Ferrari, D. ^{[4
]}

Garmey, E. ^{[4
]}

Gerber, D. ^{[5
]}

Orlov, S. ^{[6
]}

Ramlau, R. ^{[7
]}

Sequist, L. ^{[8
]}

Schiller, J. ^{[5
]}

机构：

[1] Asklepios Klinikum Gauting, Munich, Germany

[2] Univ Utah, Huntsman Canc Inst, Huntsman Canc Inst Canc Care Program, Salt Lake City, UT USA

[3] Schwarzwald Baar Clin, Schwenningen, Germany

[4] Ar Qule Inc, Woburn, MA USA

[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[6] St Petersburg Pavlov State Med Univ, St Petersburg, Russia

[7] Wielkopolskie Centrum Chorob Pluc & Gruzlicy, Poznan, Poland

[8] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S501 / S501

页数：1

共 50 条

[21] Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial
Spigel, David R.
Edelman, Martin J.
O'Byrne, Kenneth
Paz-Ares, Luis
Shames, David S.
Yu, Wei
Paton, Virginia E.
Mok, Tony
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[22] The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC).
Spigel, David R.
Edelman, Martin J.
Mok, Tony
O'Byrne, Kenneth John
Paz-Ares, Luis
Yu, Wei
Rittweger, Karen
Thurm, Holger C.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[23] Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer
Liu, Geoffrey
Cheng, D.
Ding, K.
Le Maitre, A.
Liu, N.
Patel, D.
Chen, Z.
Seymour, L.
Shepherd, F. A.
Tsao, M. S.
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) : 316 - 322
[24] Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung
Spigel, David R.
Edelman, Martin J.
O'Byrne, Kenneth
Paz-Ares, Luis
Mocci, Simonetta
Phan, See
Shames, David S.
Smith, Dustin
Yu, Wei
Paton, Virginia E.
Mok, Tony
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04) : 412 - +
[25] FINAL RESULTS OF A JAPANESE PHASE 1 TRIAL EVALUATING A C-MET INHIBITOR TIVANTINIB IN COMBINATION WITH AN EGFR INHIBITOR ERLOTINIB IN ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (ARQ 197-003/005 STUDY)
Yamamoto, N.
Murakami, H.
Takahashi, T.
Hayashi, H.
Fujisaka, Y.
Hirashima, T.
Takeda, K.
Satouchi, M.
Nakagawa, K.
ANNALS OF ONCOLOGY, 2012, 23 : 424 - 424
[26] Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer
Scagliotti, Giorgio V.
Novello, Silvia
Schiller, Joan H.
Hirsh, Vera
Sequist, Lecia V.
Soria, Jean-Charles
von Pawel, Joachim
Schwartz, Brian
Von Roemeling, Reinhard
Sandler, Alan B.
CLINICAL LUNG CANCER, 2012, 13 (05) : 391 - 395
[27] Phase I and pharmacodynamic study of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in previously treated advanced non-small cell lung cancer (NSCLC)
Gerber, David E.
Skelton, Rachael
Dong, Ying
Loudat, Laurin
Dowell, Jonathan
Boothman, David A.
Sarode, Venetia
Zhang, Wei
Xie, Yang
Gazdar, Adi
Frenkel, Eugene P.
Schiller, Joan H.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[28] Randomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).
Garon, E. B.
Dubinett, S. M.
Kabbinavar, F. F.
Reckamp, K. L.
Marquez-Garban, D. C.
Goodglick, L.
Sharma, S.
Stabile, L. P.
Siegfried, J.
Pietras, R. J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[29] Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIb or IV NSCLC: Results From the Pivotal Phase III Randomized, Multicenter, Placebo- Controlled METLung (OAM4971g) Global Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (10) : 15 - 16
[30] Final clinical results from SUNRISE: A phase III, randomized, doubleblind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer
Palmero, R.
Bidoli, P.
Bondarenko, I. M.
Boyer, M.
Germonpre, P.
Ghizdavescu, D.
Kotsakis, A.
Lena, H.
Losonczy, G.
Park, K.
Reck, M.
Su, W-C.
Kallinteris, N.
Tang, M.
Lai, J.
Shan, J.
Spigel, D. R.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →